For high-grade prostate cancer, a 5% threshold probability represents a risk-averse population, such as younger men with a long life expectancy. At a practice level, this implies that the clinician would be willing to perform as many as 20 biopsies to detect an additional high-grade cancer. ...
Predicting Life Expectancy in Men With Clinically Localized Prostate Cancer The choice of appropriate management for localized prostate cancer depends in part on the estimated life expectancy of a man. Little is known about the acc... ME Cowen,LK Halasyamani,MW Kattan - 《Journal of Urology》 被...
Radical treatment for high-risk prostate cancer among older men in Sweden according to life expectancy estimatesdoi:10.1016/S2666-1683(20)33700-9K. BeckmannJ. AdolfssonM. Van HemelrijckD. RobinsonH. GarmoEuropean Urology Open Science
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol. 2016;69(3):505-511.PubMedGoogle ScholarCrossref 52. Amin A, Partin A, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 ...
Randomized hEBRT trials with slightly different eligibility criteria are also ongoing with 48 Int J Clin Exp Med 2011;4(1):43-52 hEBRT and hEBRT for prostate cancer preliminary results published. The 5-year bC rates range from 39 to 83% with acute and late higher than grade 2 GU-TX ...
Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older? Cancers (Basel), 12 (3) (2020), p. 635 CrossrefView in ScopusGoogle Scholar Cited by (3) Does brachytherapy boost improve survival outcomes in Gleason Grade Group...
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. J Clin Invest. 2022;132: e161858. Article CAS PubMed PubMed Central Google Scholar Welsch E, Bonstingl L, Holzer B, Schuster E, Weiß E, Zaharie A-T, et al. Multi-marker analysis of circulating...
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targ
(heterogeneity), indirectness of evidence, imprecision, and publication bias. The observation of a large magnitude of an effect was used as a factor that could increase the quality of evidence. Each factor was appraised by an independent reviewer in consultation with the GRADE Handbook [52]. The...
Pancreatic cancer is among the most lethal cancers with poorly tolerated treatments. There is increasing interest in using high-dose intravenous ascorbate (IVC) in treating this disease partially because of its low toxicity. IVC bypasses bioavailability barriers of oral ingestion, provides pharmacological...